{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,4]],"date-time":"2025-11-04T23:42:11Z","timestamp":1762299731398,"version":"build-2065373602"},"reference-count":42,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","redjournal.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Radiation Oncology*Biology*Physics"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.ijrobp.2021.03.002","type":"journal-article","created":{"date-parts":[[2021,3,10]],"date-time":"2021-03-10T22:21:13Z","timestamp":1615414873000},"page":"45-52","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":8,"title":["A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer"],"prefix":"10.1016","volume":"111","author":[{"given":"Jennifer R.","family":"Bellon","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu-Hui","family":"Chen","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rebecca","family":"Rees","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Alphonse G.","family":"Taghian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Julia S.","family":"Wong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rinaa S.","family":"Punglia","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ron Y.","family":"Shiloh","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Laura E.G.","family":"Warren","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Monica S.","family":"Krishnan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"John","family":"Phillips","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jennifer","family":"Pretz","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Rachel","family":"Jimenez","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stephanie","family":"Macausland","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Itai","family":"Pashtan","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chelsea","family":"Andrews","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Steven J.","family":"Isakoff","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Eric P.","family":"Winer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sara M.","family":"Tolaney","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijrobp.2021.03.002_bib0001","doi-asserted-by":"crossref","first-page":"2087","DOI":"10.1016\/S0140-6736(05)67887-7","article-title":"Effects of radiotherapy and of differences in the extent of surgery for early breast cancer on local recurrence and 15-year survival: An overview of the randomised trials","volume":"366","author":"Clarke","year":"2005","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0002","doi-asserted-by":"crossref","first-page":"2373","DOI":"10.1200\/JCO.2007.14.4287","article-title":"Breast cancer subtype approximated by estrogen receptor, progesterone receptor, and HER-2 is associated with local and distant recurrence after breast-conserving therapy","volume":"26","author":"Nguyen","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0003","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1007\/s10549-011-1891-6","article-title":"Locoregional recurrence after breast cancer surgery: a systematic review by receptor phenotype","volume":"133","author":"Lowery","year":"2012","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0004","doi-asserted-by":"crossref","first-page":"2466","DOI":"10.1200\/JCO.2008.19.8424","article-title":"Prognosis after ipsilateral breast tumor recurrence and locoregional recurrences in patients treated by breast-conserving therapy in five National Surgical Adjuvant Breast and Bowel Project protocols of node-negative breast cancer","volume":"27","author":"Anderson","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0005","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1111\/tbj.12371","article-title":"Outcome following local-regional recurrence in women with early-stage breast cancer: Impact of biologic subtype","volume":"21","author":"Braunstein","year":"2015","journal-title":"Breast J"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0006","doi-asserted-by":"crossref","first-page":"1310","DOI":"10.1200\/JCO.1998.16.4.1310","article-title":"Chemoradiotherapy versus radiotherapy in patients with advanced nasopharyngeal cancer: Phase III randomized Intergroup study 0099","volume":"16","author":"Al-Sarraf","year":"1998","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0007","doi-asserted-by":"crossref","first-page":"987","DOI":"10.1056\/NEJMoa043330","article-title":"Radiotherapy plus concomitant and adjuvant temozolomide for glioblastoma","volume":"352","author":"Stupp","year":"2005","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0008","doi-asserted-by":"crossref","first-page":"1465","DOI":"10.1056\/NEJM198506063122301","article-title":"Prolongation of the disease-free interval in surgically treated rectal carcinoma","volume":"312","year":"1985","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0009","doi-asserted-by":"crossref","first-page":"405","DOI":"10.1200\/JCO.2006.07.8576","article-title":"Phase III trial of concurrent or sequential adjuvant chemoradiotherapy after conservative surgery for early-stage breast cancer: Final results of the ARCOSEIN trial","volume":"25","author":"Toledano","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0010","doi-asserted-by":"crossref","first-page":"1072","DOI":"10.1016\/j.ijrobp.2005.10.011","article-title":"A phase III randomized trial comparing adjuvant concomitant chemoradiotherapy versus standard adjuvant chemotherapy followed by radiotherapy in operable node-positive breast cancer: Final results","volume":"64","author":"Rouesse","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0011","first-page":"185","article-title":"Concurrent chemotherapy and radiation for breast conservation treatment of early-stage breast cancer","volume":"4","author":"Markiewicz","year":"1998","journal-title":"Cancer J Sci Am"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0012","doi-asserted-by":"crossref","first-page":"2085","DOI":"10.1200\/JCO.2007.15.2488","article-title":"A multicenter randomized trial of breast intensity-modulated radiation therapy to reduce acute radiation dermatitis","volume":"26","author":"Pignol","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0013","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.radonc.2006.12.008","article-title":"Randomised trial of standard 2D radiotherapy (RT) versus intensity modulated radiotherapy (IMRT) in patients prescribed breast radiotherapy","volume":"82","author":"Donovan","year":"2007","journal-title":"Radiother Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0014","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1016\/j.canlet.2012.01.007","article-title":"DNA damage-induced cell death: From specific DNA lesions to the DNA damage response and apoptosis","volume":"332","author":"Roos","year":"2013","journal-title":"Cancer Lett"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0015","doi-asserted-by":"crossref","DOI":"10.4061\/2010\/201367","article-title":"Cellular responses to Cisplatin-induced DNA damage","author":"Basu","year":"2010","journal-title":"J Nucleic Acids"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0016","doi-asserted-by":"crossref","first-page":"110","DOI":"10.1038\/nrc.2015.21","article-title":"BRCAness revisited","volume":"16","author":"Lord","year":"2016","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0017","doi-asserted-by":"crossref","first-page":"277","DOI":"10.1158\/1541-7786.MCR-04-0032","article-title":"Cisplatin sensitizes cancer cells to ionizing radiation via inhibition of nonhomologous end joining","volume":"3","author":"Boeckman","year":"2005","journal-title":"Mol Cancer Res"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0018","doi-asserted-by":"crossref","first-page":"1339","DOI":"10.1200\/JCO.1999.17.5.1339","article-title":"Randomized comparison of fluorouracil plus cisplatin versus hydroxyurea as an adjunct to radiation therapy in stage IIB-IVA carcinoma of the cervix with negative para-aortic lymph nodes: A Gynecologic Oncology Group and Southwest Oncology Group study","volume":"17","author":"Whitney","year":"1999","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0019","doi-asserted-by":"crossref","first-page":"1144","DOI":"10.1056\/NEJM199904153401502","article-title":"Concurrent cisplatin-based radiotherapy and chemotherapy for locally advanced cervical cancer","volume":"340","author":"Rose","year":"1999","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0020","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1056\/NEJMoa032646","article-title":"Postoperative concurrent radiotherapy and chemotherapy for high-risk squamous-cell carcinoma of the head and neck","volume":"350","author":"Cooper","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0021","doi-asserted-by":"crossref","first-page":"4701","DOI":"10.1200\/JCO.2008.21.7075","article-title":"Prediction of local recurrence, distant metastases, and death after breast-conserving therapy in early-stage invasive breast cancer using a five-biomarker panel","volume":"27","author":"Millar","year":"2009","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0022","doi-asserted-by":"crossref","first-page":"1684","DOI":"10.1200\/JCO.2009.24.9284","article-title":"Breast cancer subtypes and the risk of local and regional relapse","volume":"28","author":"Voduc","year":"2010","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0023","doi-asserted-by":"crossref","first-page":"164","DOI":"10.1016\/S0140-6736(13)62422-8","article-title":"Pathological complete response and long-term clinical benefit in breast cancer: the CTNeoBC pooled analysis","volume":"384","author":"Cortazar","year":"2014","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0024","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1245\/s10434-015-4921-5","article-title":"Locoregional control according to breast cancer subtype and response to neoadjuvant chemotherapy in breast cancer patients undergoing breast-conserving therapy","volume":"23","author":"Swisher","year":"2016","journal-title":"Ann Surg Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0025","doi-asserted-by":"crossref","first-page":"e8252","DOI":"10.1097\/MD.0000000000008252","article-title":"Randomized controlled trial of late-course concurrent versus sequential chemoradiotherapy after mastectomy and axillary surgery in locally advanced breast cancer","volume":"96","author":"Lu","year":"2017","journal-title":"Medicine (Baltimore)"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0026","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1186\/s13014-019-1321-1","article-title":"Prospective results of concurrent radiation therapy and weekly paclitaxel as salvage therapy for unresectable locoregionally recurrent breast cancer","volume":"14","author":"Cai","year":"2019","journal-title":"Radiat Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0027","doi-asserted-by":"crossref","first-page":"1806","DOI":"10.1093\/jnci\/93.23.1806","article-title":"Risk of pneumonitis in breast cancer patients treated with radiation therapy and combination chemotherapy with paclitaxel","volume":"93","author":"Taghian","year":"2001","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0028","doi-asserted-by":"crossref","first-page":"5755","DOI":"10.1200\/JCO.2008.17.7840","article-title":"Phase III study of cisplatin, etoposide, and concurrent chest radiation with or without consolidation docetaxel in patients with inoperable stage III non-small-cell lung cancer: The Hoosier Oncology Group and U.S. Oncology","volume":"26","author":"Hanna","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0029","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1016\/j.ijrobp.2005.07.975","article-title":"Prospective evaluation of concurrent paclitaxel and radiation therapy after adjuvant doxorubicin and cyclophosphamide chemotherapy for stage II or III breast cancer","volume":"64","author":"Burstein","year":"2006","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0030","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1016\/j.ijrobp.2010.08.051","article-title":"A phase II study of radiotherapy and concurrent paclitaxel chemotherapy in breast-conserving treatment for node-positive breast cancer","volume":"82","author":"Chen","year":"2012","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0031","doi-asserted-by":"crossref","first-page":"393","DOI":"10.1016\/S0360-3016(00)00636-2","article-title":"Concurrent radiation therapy and paclitaxel or docetaxel chemotherapy in high-risk breast cancer","volume":"48","author":"Bellon","year":"2000","journal-title":"Int J Radiat Oncol Biol Phys"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0032","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1200\/JCO.2014.57.0572","volume":"33","author":"Sikov","year":"2015","journal-title":"J Clin Oncol"},{"issue":"suppl 15","key":"10.1016\/j.ijrobp.2021.03.002_bib0033","article-title":"Phase III trial of metronomic capecitabine maintenance after standard treatment in operable triple-negative breast cancer (SYSUCC-001)","volume":"38","author":"Wang","year":"2020","journal-title":"J Clin Oncol"},{"issue":"suppl 4","key":"10.1016\/j.ijrobp.2021.03.002_bib0034","article-title":"Abstract GS2-04: Efficacy results from CIBOMA\/2004-01_GEICAM\/2003-11 study: A randomized phase III trial assessing adjuvant capecitabine after standard chemotherapy for patients with early triple negative breast cancer","volume":"79","author":"Mart\u00edn","year":"2019","journal-title":"Cancer Res"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0035","doi-asserted-by":"crossref","first-page":"2147","DOI":"10.1056\/NEJMoa1612645","article-title":"Adjuvant Capecitabine for Breast Cancer after Preoperative Chemotherapy","volume":"376","author":"Masuda","year":"2017","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0036","doi-asserted-by":"crossref","first-page":"203","DOI":"10.1200\/JCO.19.00904","article-title":"Phase III trial of adjuvant capecitabine after standard neo-\/adjuvant chemotherapy in patients with early triple-negative breast cancer (GEICAM\/2003-11_CIBOMA\/2004-01)","volume":"38","author":"Lluch","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0037","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1016\/S1470-2045(14)70160-3","article-title":"Neoadjuvant carboplatin in patients with triple-negative and HER2-positive early breast cancer (GeparSixto; GBG 66): A randomised phase 2 trial","volume":"15","author":"von Minckwitz","year":"2014","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0038","doi-asserted-by":"crossref","first-page":"1518","DOI":"10.1016\/j.annonc.2020.08.2064","article-title":"TBCRC 030: A phase II study of preoperative cisplatin versus paclitaxel in triple-negative breast cancer: Evaluating the homologous recombination deficiency (HRD) biomarker","volume":"31","author":"Mayer","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0039","doi-asserted-by":"crossref","first-page":"3764","DOI":"10.1158\/1078-0432.CCR-15-2477","article-title":"Homologous recombination deficiency (HRD) score predicts response to platinum-containing neoadjuvant chemotherapy in patients with triple-negative breast cancer","volume":"22","author":"Telli","year":"2016","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0040","doi-asserted-by":"crossref","first-page":"e108","DOI":"10.1056\/NEJMoa1910549","article-title":"Pembrolizumab for early triple-negative breast cancer. Reply","volume":"382","author":"Schmid","year":"2020","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0041","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1016\/S0140-6736(20)31953-X","article-title":"Neoadjuvant atezolizumab in combination with sequential nab-paclitaxel and anthracycline-based chemotherapy versus placebo and chemotherapy in patients with early-stage triple-negative breast cancer (IMpassion031): A randomised, double-blind, phase 3 trial","volume":"396","author":"Mittendorf","year":"2020","journal-title":"Lancet"},{"key":"10.1016\/j.ijrobp.2021.03.002_bib0042","doi-asserted-by":"crossref","first-page":"1317","DOI":"10.1200\/JCO.2017.77.2665","article-title":"Concurrent veliparib with chest wall and nodal radiotherapy in patients with inflammatory or locoregionally recurrent breast cancer: The TBCRC 024 phase I multicenter study","volume":"36","author":"Jagsi","year":"2018","journal-title":"J Clin Oncol"}],"container-title":["International Journal of Radiation Oncology*Biology*Physics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162100242X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S036030162100242X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,6]],"date-time":"2025-10-06T09:52:19Z","timestamp":1759744339000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S036030162100242X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":42,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,9]]}},"alternative-id":["S036030162100242X"],"URL":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.002","relation":{},"ISSN":["0360-3016"],"issn-type":[{"type":"print","value":"0360-3016"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A Phase 1 Dose-Escalation Trial of Radiation Therapy and Concurrent Cisplatin for Stage II and III Triple-Negative Breast Cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Radiation Oncology*Biology*Physics","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijrobp.2021.03.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}